Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors

Transcription

1 Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors Alfieri Ottavio Andreotti Felicita Antunes Manuel J - Valtech : Mitral products (2011) - Edwards Lifesciences : Prosthetic rings (2011) - Symetis SA : Transapical aortic prosthesis (2011) - Valtech : Mitral rings (2010) - Symetis SA : Transcatheter aortic valve (2010) C - Receipt of royalties for intellectual property. - Edwards Lifesciences : Mitral rings (2010) - Pfizer : Anticoagulant agent (2010) - Bristol Myers Squibb : Anticoagulant agent (2010) - Astra Zeneca : Antiplatelet agent (2010) - Daiichi Sankyo : Antiplatelet agent (2010) - Eli Lilly : Antiplatelet agent (2010) - Bayer Healthcare : Antiplatelet agent; Anticoagulant agent (2010) - Bayer Schering Pharma : Aspirin, rivaroxaban (2011) - BMS-Pfizer : Apixaban, cardiovascular metabolism (2011) - Pfizer (see also BMS) : Apixaban (2011) - Daiichi Sankyo : Edoxaban (2011) - Eli Lilly : Prasugrel (2011) - Edwards Lifesciences : Occasional activity - Mitral valve repair- Carpentir Edwards ring (2011) - Edwards Lifesciences : Occasional speaker fees / expenses (2010) 08/25/2012 Page 1 of 23

2 Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors Baron Esquivias Gonzalo Baumgartner Helmut Borger Michael A Carrel Thierry - St Jude Medical : Occasional speaker fees / expenses (2010) - Bayer : Anticoagulation ( ) - Boehringer-Ingelheim : Anticoagulation ( ) - Bristol Myers Squibb : Anticoagulation (2010) - Rovi : Dislypidemia (2011) - Actelion : Bosentan for PAH treatment in congenital heart disease ( ) - AGA : Devices for catheter treatment of congenital heart defects (2010) - Edwards Lifesciences : transcatheter valve implantation (2011) - Edwards Lifesciences : transcatheter valve implantation (2010) - Actelion : Bosentan for PAH treatment in congenital heart disease (2011) - Edwards Lifesciences : transcatheter valve implantation (2011) - Edwards Lifesciences : heart valve therapy ( ) - St Jude Medical : heart valve therapy (2010) - St Jude Medical : heart valve therapy (2011) C - Receipt of royalties for intellectual property. - Medtronic : heart valve therapy (2010) - Medtronic : heart valve therapy (2011) - ATS : Heart Valves (2010) - Edwards Lifesciences : Heart Valves (2011) 08/25/2012 Page 2 of 23

3 Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors De Bonis Michele Evangelista Masip Artur Falk Volkmar - Edwards Lifesciences : Heart Valves (2010) - Medtronic : Heart Valves (2011) - ATS : Heart Valves (2010) - Medtronic : Heart Valves (2010) - St Jude Medical : Heart Valves (2010) - Medtronic : Heart Valves, Endovascular Stent-Grafts (2011) - Edwards Lifesciences : Heart Valves (2011) - Sorin Group : Heart Valves (2010) - St Jude Medical : Anticoagulation (2011) E - Research funding (personal). - Bayer : Anticoagulation (2011) None - Nadirex International srl : Ventricular Assist Devices (2011) - Valtech : minimally invasive mitral valve surgery (adjustable rings, chordae) (2010) - Edwards Lifesciences : Valves (2011) - Medtronic : valves (2011) - Valtech : Valves (2011) - Medtronic : heart valves (2010) C - Receipt of royalties for intellectual property. 08/25/2012 Page 3 of 23

4 Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors Iung Bernard Lancellotti Patrizio Pierard Luc - St Jude Medical : heart valves (2010) - Edwards Lifesciences : heart valves, rings (2010) - Philips : Imaging (2011) - Servier : benfluorex ( ) - Boehringer-Ingelheim : dabigatran ( ) - Edwards Lifesciences : heart valve prosthesis ( ) - St Jude Medical : heart valve prosthesis (2010) - Abbott : Mitraclip ( ) - Sanofi Aventis : None (educational program) ( ) - Bayer : rivaroxaban ( ) - Boston Scientific : Heart Failure (2011) -,astra zeneca, boheringer, menarini : pradaxa, belsar, crestor (2010) - Bayer Healthcare : Xarelto (2011) - Actelion : tracleer (2010) - Servier : Coversyl (2011) - Astra Zeneca : Crestor (2011) - Novartis : Aliskiren (2011) - Astra Zeneca : Rosuvastatin Ticagrelor (2011) - General Electric : VIVID 9 (2011) 08/25/2012 Page 4 of 23

5 Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors Price Susanna Schaefers Hans-Joachim Schuler Gerhard Stepinska Janina - Novartis : Aliskiren (2010) - Merck Sharp & Dohme : Ezetimibe (2010) - General Electric : No (2010) - Astra Zeneca : Rosuvastatine (2010) - Astra Zeneca : Rosuvastatine (2011) - Astra Zeneca : Rosuvastatine (2010) - Abbott : Consultant ( ) - Medtronic : Honoraria for educational lectures (1-2 per annum) ( ) - Edwards Lifesciences : DSMB, speaker (2010) - St Jude Medical : speaker (2010) - Edwards Lifesciences : speaker (2011) - St Jude Medical : speaker (2011) - Edwards Lifesciences : Percutaneous Valves ( ) - Boston Scientific : Watchman Device (2011) - Medtronic : Stents (2010) - Medtronic : Stents (2011) - Boehringer-Ingelheim : anticoagulation (2011) 08/25/2012 Page 5 of 23

6 Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors Swedberg Karl - Boehringer-Ingelheim : anticoagulation (2010) - Bristol Myers Squibb : anticoagulation (2011) - Bristol Myers Squibb : anticoagulation (2010) - Egis Pharma : anticoagulation (2010) - Eli Lilly : anticoagulation/prasugrel (2010) - Bayer Healthcare : anticoagulation/rivaroxaban ( ) - Astra Zeneca : anticoagulation/ticagrelor (2010) - Sanofi Aventis : antiplatelet, antiarrhythmic (2010) - Astra Zeneca : antiplatelet/ticagrelor (2011) - Merck Sharp & Dohme : lipid lowering therapy (2010) - Servier : registry, NC (2010) - Astra Zeneca : ACS, registry (2011) - Cothera : acute heart failure/relaxin (2011) - Bayer : atrial fibrillation, registry (2011) - Sanofi Aventis : dronedaron (2011) - Servier : stable angina, registry (2011) - Trevena : TRV120027, stable heart failure (2011) - Astra Zeneca : candesartan (2010) - Amgen : Heart failure (2011) - Novartis : Heart failure (2011) - Servier : ivabradine (2011) 08/25/2012 Page 6 of 23

7 Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors Takkenberg Jjm Vahanian Alec - Amgen Inc : darbepoetin (2010) - Amgen Inc : darbepoetin (2011) - Servier : heart failure (2011) - Novartis, Astra-Zeneca, Menarini, Bayer, Takeda, Daiichi-Sankyo, Otsuka, Servier : several (2010) - Amgen : heart failure (2011) E - Research funding (personal). - Amgen : darbepoetin (2010) - Cryolife : human tissue valves (2010) - Sorin Group : prosthetic valves (2010) - Cryolife : human tissue valves (2011) - Sorin Group : prosthetic valves (2011) - Abbott : valve disease (2011) - Valtech : valve disease (2011) - Medtronic Foundation : valve disease (2011) - saint Jude medical : valve disease (2011) - Edwards Life sciences : valve disease (2011) - Abbott : Valve prostheses (2010) - Boehringer-Ingelheim : Valve prostheses (2010) - Edwards Lifesciences : Valve prostheses (2010) 08/25/2012 Page 7 of 23

8 Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors von Oppell Ulrich Windecker Stephan - Medtronic : Valve prostheses (2010) - Valtech : Valve prostheses (2010) - Siemens Healthcare : Valve prostheses (2010) - St Jude Medical : Aortic & Mitral Valve surgery ( ) - Vascutek Ltd : Aortic grafts (2010) - Vascutek Ltd : Aortic Valve repair and Aortic grafts (2011) - Medtronic : Mitral Valve Repair & Atrial fibrillation surgery ( ) - Medtronic : Aortic valve trial (2010) - Astra Zeneca : Antiplatelet drug ( ) - Eli Lilly : Antiplatelet drug ( ) - Abbott : Stent ( ) - Biosensors : Stent ( ) - Boston Scientific : Stent ( ) - Medtronic : Stent ( ) - Biotronik : Stent ( ) - Cordis : Stent ( ) - Abbott : Stent (2010) - Biosensors : Stent (2010) - Medtronic : Stent (2010) - Cordis : Stent (2010) 08/25/2012 Page 8 of 23

9 Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors Zamorano Gomez Jose Luis Zembala Marian - St Jude Medical : OCT (2011) - Abbott : Stent (2011) - Biosensors : Stent (2011) - Medtronic : Stent (2011) - Biotronik : Stent (2011) - Cordis : Stent (2011) - Daiichi Sankyo : Anticoagulation (2010) None - Philips : Imaging (2010) - Merck Sharp & Dohme : Lipids (2010) - Abbott Vascular : IMAGING IN HF (2011) - Merck Sharp & Dohme : LIPIDS (2011) This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines. 08/25/2012 Page 9 of 23

10 Guidelines on Valvular Heart Disease (TF29) - Document Reviewers Badano Luigi Paolo Bunc Matjaz Claeys Marc Drinkovic Niksa Filippatos Gerasimos - Malesci : Hypertension, hypercholesterolemia (2010) - Medtronic : Medical devices (2010) - GE Healthcare : Medical devices (2010) - Actelion : Pulmonary hypertension (2010) - GE Healthcare : medical devices (2010) None - Medicines Company : bivalirudine ( ) - Eli Lilly : prasugrel, abciximab ( ) - Abbott Vascular : stents (2010) - Abbott Vascular : stents- mitraclip (2011) - Astra Zeneca : ticagrelor ( ) - Medtronic : coronary stent and corevalve (2010) None - Medtronic : coronary stent and corevalve (2011) - Torrent : Heart failure (2010) - Vifor International : Heart failure (2010) - Corthera, Novartis : Heart failure (2010) 08/25/2012 Page 10 of 23

11 Guidelines on Valvular Heart Disease (TF29) - Document Reviewers Habib Gilbert Kappetein A Pieter Kassab Roland Youssef - BRAHMS GmbH : Biomarkers (2010) - Roche Pharma : Biomarkers (2010) E - Research funding (personal). - Nanosphere : Biomarkers (2010) - European Union : Heart failure (2010) - Astra Zeneca : heart failure (2010) - Pfizer : pulmonary hypertension ( ) - Actelion : pulmonary hypertension ( ) - Lilly : pulmonary hypertension (2010) - Medtronic : Transcatheter heart valve (steering committee member) (2010) - Atricure : atrial fibrillation (2011) - Boston Scientific : Coronary stenosis (2011) - Abbott Vascular : Coronary stenosis (2011) - Edwards Lifesciences : Valves (2011) - Medtronic : Valves (2011) - Abbott Vascular : Valves (2011) - Astra Zeneca : New Oral Anticoagulation (2011) - Astra Zeneca : Speaker fees, Advisory board fees, from several companies (2010) 08/25/2012 Page 11 of 23

12 Guidelines on Valvular Heart Disease (TF29) - Document Reviewers Lip Gregory Yh Moat Neil - Biotronik : atrial fibrillation ( ) - Portola Pharmaceuticals : atrial fibrillation (2010) - Merck Sharp & Dohme : atrial fibrillation (2010) - BMS : atrial fibrillation, thrombosis ( ) - Boehringer-Ingelheim : atrial fibrillation, thrombosis ( ) - Pfizer : atrial fibrillation, thrombosis ( ) - Bayer Healthcare : atrial fibrillation, thrombosis (2011) - Astellas : atrial fibrillation, thrombosis (2011) - Astellas : atrial fibrillation, thrombosis (2010) - Bayer Schering Pharma : atrial fibrillation, thrombosis (2010) - Daiichi Sankyo : atrial fibrillation, thrombosis [sums from each] (2010) - Boehringer-Ingelheim : atrial fibrillation, thrombosis (2010) - Bayer Schering Pharma : atrial fibrillation, thrombosis (2010) - Bayer Healthcare : atrial fibrillation, thrombosis (2010) - Bayer : atrial fibrillation, thrombosis (2011) - Medtronic : CoreValve (2010) - Medtronic : CoreValve (2011) - Abbott Vascular : Mitraclip (2010) - Edwards Lifesciences : Physio annuloplasty systems (2010) - Abbott Vascular : Mitraclip (2011) 08/25/2012 Page 12 of 23

13 Guidelines on Valvular Heart Disease (TF29) - Document Reviewers Nickenig Georg Otto Catherine M Pepper John Piazza Nicolo Pieper Els Petronella G None C - Receipt of royalties for intellectual property. - Elsevier : Medical texbooks (2010) - Up to Date : Online medical informaton (2010) - Covidien : Near infra-red spectroscopy (2010) - Medtronic : Transcatheter Aortic Valve ( ) - CardiaAQ : Transcatheter Mitral Valve (2010) - CardiaAQ : Transcatheter Mitral Valve (2011) - Sorin Group : funding for research on prosthetic heart valves in congenital heart disease (prostava study); total amount euro; Main funding of this project is by Netherlands Heart Foundation. Funders have had no saying in the design of the study and will not be involved in the scientific output arising from this study (2010) - Sorin Group : funding for research on prosthetic heart valves in congenital heart disease (prostava study); total amount euro; Main funding of this project is by Netherlands Heart Foundation. Funders have had no saying in the design of the study and will not be involved in the scientific output arising from this study (2011) Popescu Bogdan Alexandru - GE Healthcare : Imaging ( ) Rosenhek Raphael - Edwards Lifesciences : Valvular heart disease (2010) - Edwards Lifesciences : Valvular heart disease (2011) 08/25/2012 Page 13 of 23

14 Guidelines on Valvular Heart Disease (TF29) - Document Reviewers Schwammenthal Ehud Schwitter Juerg Shuka Naltin Tornos Mas Pilar Trigo Trindade Pedro - Medtronic : Consultant to Medtronic Ventor (transcatheter valve products, cardiovascular devices) ( ) - Bayer : Xarelto (2010) - Bayer : Xarelto (2011) - Bayer : not applicable (2010) None - Medtronic : not applicable (2010) - Bayer : not applicable (2011) - Medtronic : not applicable (2011) - Bracco Pharmaceutical : not applicable (2011) - Servier : Consultancu (2011) None - Boehringer-Ingelheim : dabigatran Speaker fees (2010) - Servier : ivabradine Speker fees (2010) - Abbott : Mitral clip. Consultancy (2011) - Bayer : Speaker fees (2011) - Boehringer-Ingelheim : Speaker fees (2011) - Edwards Lifesciences : speaker fees mitral valve repair meeting (2010) von Segesser Ludwig K 08/25/2012 Page 14 of 23

15 Guidelines on Valvular Heart Disease (TF29) - Document Reviewers Walther Thomas - Symetis SA : Catheter valves ( ) - Swiss Heart Foundation : Promotê information, education and resaerch in the cardio-vascular field ( ) - Smartcanula LLC : Self-expanding cannulas ( ) - Edwards Lifesciences : Transcatheter heart valve (2010) This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines. 08/25/2012 Page 15 of 23

16 ESC Committee for Practice Guidelines Baumgartner Helmut Bax Jeroen - Actelion : Bosentan for PAH treatment in congenital heart disease ( ) - AGA : Devices for catheter treatment of congenital heart defects (2010) - Edwards Lifesciences : transcatheter valve implantation (2011) - Edwards Lifesciences : transcatheter valve implantation (2010) - Actelion : Bosentan for PAH treatment in congenital heart disease (2011) - Edwards Lifesciences : transcatheter valve implantation (2011) - Heart.org : Education (2010) - Astra Zeneca : Farma (2010) - Servier : Farma (2010) - Philips : Imaging (2010) - GE Healthcare : Imaging (2010) - Lantheus Inc : Imaging (2010) - Boston Scientific : Pacing (2010) - Medtronic : Pacing (2010) - St Jude Medical : Pacing (2010) - Biotronik : Pacing (2010) - Impulse Dynamics : Pacing (2010) - Servier : Farma (2010) - Edwards Lifesciences : Heart Valves (2010) - GE Healthcare : Imaging (2010) - Lantheus Inc : Imaging (2010) - Boston Scientific : Pacing (2010) - Medtronic : Pacing (2010) - St Jude Medical : Pacing (2010) - Biotronik : Pacing (2010) - Servier : Farma (2011) - Edwards Lifesciences : Heart Valves (2011) - GE Healthcare : Imaging (2011) - Lantheus Inc : Imaging (2011) - Boston Scientific : Pacing (2011) 08/25/2012 Page 16 of 23

17 ESC Committee for Practice Guidelines Ceconi Claudio Deaton M Christi Fagard Robert Funck-Brentano Christian Hasdai David - Medtronic : Pacing (2011) - St Jude Medical : Pacing (2011) - Biotronik : Pacing (2011) - Servier : Pharmaceutical ( ) - St Jude Medical : Cath lab - speaker X 1 (2010) - Daiichi Sankyo : consultant for patient adherence (2010) - Eli Lilly : consultant for patient adherence (2010) - Novo-Nordisk : medicines for diabetes (2010) - Novo-Nordisk : patients with heart failure and diabetes (2011) - Servier : Honorarium for manuscript (2011) - Servier : Honorarium for manuscript in Medicographia (2010) - Novartis CH : Adjudication Committee on an immunosuppressant (2011) - Lundbeck : Cardiac safety of an antidepressant (2011) - Pierre-Fabre : Cardiac Safety of non-cardiovasclar products ( ) - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. ( ) - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - MMV (CH) : Cardiac Saftey of an antimalarial drug ( ) - Santhera (CH) : Cardiac Saftey of an antimalarial drug ( ) - Sigma Tau : Cardiac Saftey of an antimalarial drug ( ) - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis Cardiac safety ( ) - CEPHALON : DSMB in an oncology phase IIb trial ( ) - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel ( ) - Intracellular Therapies USA : Psyhotropic drug developement (2011) - Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel (2010) - Sanofi Aventis : Enoxaparin (2010) - Boehringer-Ingelheim : Pradaxa (2011) 08/25/2012 Page 17 of 23

18 ESC Committee for Practice Guidelines Hoes Arno Kirchhof Paulus Knuuti Juhani - Bayer : Rivaroxiban (2011) - Astra Zeneca : Ticagrelor (2011) - Eli Lilly : Effient (2011) - Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips - Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from - Bayer Healthcare : unresctricted grant for diagnostic kits in suspected cardiovascualar disease (2010) - Abbott Laboratories : unresctricted grant for diagnostic kits in suspected cardiovascualar disease (2010) - Roche Pharma : unresctricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome (2010) - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2011) - BMS : cardiovascular (2011) - Boehringer-Ingelheim : cardiovascular (2011) - Daiichi Sankyo : cardiovascular (2011) - Medtronic : cardiovascular (2011) - St Jude Medical : cardiovascular (2011) - Sanofi Aventis : cardiovascular (2011) - Meda pharma : cardiovascular (2011) - Merck Sharp & Dohme : cardiovascular (2011) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2011) - St Jude Medical : cardiovascular (2011) - Sanofi Aventis : cardiovascular (2011) - Meda pharma : cardiovascular (2011) - Lantheus Inc : Imaging tracers (2010) - Lantheus Inc : Perfusion imaging tracer development (2011) 08/25/2012 Page 18 of 23

19 ESC Committee for Practice Guidelines Kolh Philippe H - Bayer : Development of imaging agents (2010) - Novartis : Development of imaging agents (2010) - GE Healthcare : Development of imaging agents (2010) - Lantheus Inc : Development of imaging agents (2010) - Roche Pharma : Drugs for brain diseases (2010) - Astra Zeneca : Neurology (2011) - GE Healthcare : Neurology and molecular imaging (2011) - Merck Sharp & Dohme : Antiarrhythmic agents (2010) - Merck Sharp & Dohme : Antiarrythmic agents (2011) - Astra Zeneca : Antiplatelet agents ( ) - Bristol Myers Squibb : Antiplatelet agents (2010) - Regado Biosciences : Antithrombotic agents ( ) - Abbott : coronary stents (2010) - Abbott Vascular : Coronary stents (2011) - Merck Sharp & Dohme : Antistaphylococcic vaccine (2010) - Merck Sharp & Dohme : Antistaphylococcic vaccine (2011) - Edwards Lifesciences : Cardiac valves (2010) - Medtronic : Cardiac valves (2010) - St Jude Medical : Cardiac valves (2010) - Siemens Healthcare : Imaging (2010) - Johnson & Johnson : Thoracoscopic devices (2010) - Edwards Lifesciences : Cardiac valves (2011) - Medtronic : Cardiac valves (2011) - St Jude Medical : Cardiac valves (2011) - Boston Scientific : Coronary stents (2011) - Siemens Healthcare : Medical imaging (2011) - Johnson & Johnson : Thoracoscopic devices (2011) 08/25/2012 Page 19 of 23

20 ESC Committee for Practice Guidelines McDonagh Theresa Popescu Bogdan Alexandru Reiner Zeljko Sechtem Udo Sirnes Per Anton - Vifor International : Ferrinject ( ) - Servier : Ivabridine (2010) - Servier : Ivabridine (2011) - Biotronik : CRT (2010) - GE Healthcare : Imaging ( ) - Bayer : anticoagulants (2011) - Bayer Healthcare : anticoagulants (2010) - Abbott : antilipemics (2010) - Astra Zeneca : antilipemics ( ) - Pfizer : antilipemics ( ) - Sanofi Aventis : antilipemics (2011) - Abbott Laboratories : antilipemics (2011) - Merck Sharp & Dohme : antilipemics (2010) - Merck Sharp & Dohme : antilipemics (2011) - Boehringer-Ingelheim : Anticoagulation ( ) - Daiichi Sankyo : Antiplatelet therapy (2010) - Novartis : Drugs ( ) - Pfizer : Drugs (2011) - Siemens Healthcare : Imaging (2010) - General Electric : Imaging (2010) - Novartis : Imaging devices (2010) - Johnson & Johnson : Stents (2010) - Novartis : Drugs (2011) - Johnson & Johnson : Stents (2011) 08/25/2012 Page 20 of 23

21 ESC Committee for Practice Guidelines Tendera Michal Torbicki Adam - Bayer : clinical studies atrial fibrillation investigator fee (ROCKET) (2010) - Merck Sharp & Dohme : investgator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2010) - GlaxoSmithKline : investigator fee, clinical study, SCAD (2010) - Sanofi Aventis : investigator fee, clinical study (PALLAS) (2010) - Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2010) - Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2010) - Boehringer-Ingelheim : investigator fee, clinicla study, AF (RELY. RELYABLE) (2010) - Merck Sharp & Dohme : investgator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2011) - GlaxoSmithKline : investigator fee, clinical study, SCAD (2011) - Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2011) - Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2011) - Bayer : Aspirin, Rivaroxaban (2011) - Amgen : Darbopoietin (2011) - Servier : Ivabradine, Phase II investigational products (2011) - Servier : Ivabradine, Phase II investigational products (2011) - TIMI group : Rivaroxaban (2011) - Boehringer-Ingelheim : anticoagulation (2010) - Sanofi Aventis : anticoagulation (2010) - Pfizer : anticoagulation, pulmonary hypertension (2010) - United Therapeutics : Pulmonary arterial hypertension (2011) - GSK : pulmonary arterial hypertension - ambrisentan (2011) - Actelion : pulmonary arterial hypertension - macisentan, selexipag (2011) - Lilly : pulmonary arterial hypertension - tadalafil (2011) - AOP : Pulmonary arterial hypertension - treprostinil (2011) - Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat (2011) - Actelion : pulmonary hypertension (2010) - Lilly : pulmonary hypertension (2010) - Bayer Healthcare : pulmonary hypertension, anticoagulation (2010) - Bristol Myers Squibb : thromboembolic disease - Apixaban (2011) 08/25/2012 Page 21 of 23

22 ESC Committee for Practice Guidelines Vahanian Alec Windecker Stephan - Bayer Healthcare : Pulmonary hypertension (2011) - Sanofi Aventis : Thromboembolic disease (2011) - Abbott : valve disease (2011) - Valtech : valve disease (2011) - Medtronic Foundation : valve disease (2011) - saint Jude medical : valve disease (2011) - Edwards Life sciences : valve disease (2011) - Abbott : Valve prostheses (2010) - Boehringer-Ingelheim : Valve prostheses (2010) - Edwards Lifesciences : Valve prostheses (2010) - Medtronic : Valve prostheses (2010) - Valtech : Valve prostheses (2010) - Siemens Healthcare : Valve prostheses (2010) - Astra Zeneca : Antiplatelet drug ( ) - Eli Lilly : Antiplatelet drug ( ) - Abbott : Stent ( ) - Biosensors : Stent ( ) - Boston Scientific : Stent ( ) - Medtronic : Stent ( ) - Biotronik : Stent ( ) - Cordis : Stent ( ) - Abbott : Stent (2010) - Biosensors : Stent (2010) - Medtronic : Stent (2010) - Cordis : Stent (2010) - St Jude Medical : OCT (2011) - Abbott : Stent (2011) - Biosensors : Stent (2011) - Medtronic : Stent (2011) - Biotronik : Stent (2011) 08/25/2012 Page 22 of 23

23 ESC Committee for Practice Guidelines Cordis : Stent (2011) This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines. 08/25/2012 Page 23 of 23